Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine

[Objective] There is limited evidence on whether dolutegravir/lamivudine (DTG/3TC) reduces the viral reservoir, immune activation, and inflammation as a three-drug regimen. This study aims to clarify possible differences in these outcomes in people with HIV-1 (PHIV) starting DTG plus tenofovir alafe...

Descripción completa

Detalles Bibliográficos
Autores: Saborido-Alconchel, Abraham, Serna, Ana, Trujillo-Rodríguez, María, Muñoz-Muela, Esperanza, Álvarez-Ríos, Ana Isabel, Sotomayor, César, Herrero, Marta, López-Cortés, Luis Eduardo, Espinosa, Nuria, Raffo, Miguel, Romero-Palacios, Alberto, Mariscal-Vázquez, Gabriel, Rivero, Antonio, Roca-Oporto, Cristina, Gutiérrez Valencia, Alicia, López-Cortés, Luis F.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::558aad440dae50046323396e6bee725d
Acceso en línea:http://hdl.handle.net/10261/431825
https://api.elsevier.com/content/abstract/scopus_id/105025000303
Access Level:acceso abierto
Palabra clave:Dolutegravir
HIV-1 reservoir
HIV-1 treatment
Three-drug regimen
Two-drug regimen
Descripción
Sumario:[Objective] There is limited evidence on whether dolutegravir/lamivudine (DTG/3TC) reduces the viral reservoir, immune activation, and inflammation as a three-drug regimen. This study aims to clarify possible differences in these outcomes in people with HIV-1 (PHIV) starting DTG plus tenofovir alafenamide/emtricitabine (DTG + TAF/F) versus DTG/3TC.

Similares en LA Referencia